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apid real time surveillance and monitoring of pandemic
nﬂuenza associated pneumonia & risk factors using pri-
ary care electronic medical records (EMR)
. Wong1, J.G. Mercer2, S. Mukhi1, S. Totten1,∗, K. El
man3, G. Jayaraman1, C. Babin1, R. Saginur3, R. Kropp1,
. Rodin1, G. Garber3
Public Health Agency of Canada, Ottawa, ON, Canada
Canadian Medical Association, Ottawa, ON, Canada
University of Ottawa, Ottawa, ON, Canada
Background: The arrival of the inﬂuenza pandemic
pH1N1) highlights gaps in surveillance. This pilot project
everages EMR to rapidly detect changes in the severity of
nﬂuenza-like-illness (ILI) and associated risk factors to sup-
ort public health actions.
Methods: The sentinel primary care clinics use their
MR with minimal operational disruption to transmit de-
dentiﬁed surveillance information daily to the secure
anadian Network for Public Health Intelligence (CNPHI)
erver at the Public Health Agency of Canada. The Canadian
luWatch ILI case deﬁnition is used:
fever (T > 38 0C) and
cough and
myalgia or arthralgia or sore throat or fatigue.
Chi-Square, Fisher Exact and Mann-Whitney tests, with
< 0.05 (2-sided) denoting statistical signiﬁcance are used.
Results: During the initial phase of the 12 month study
Oct 4-Nov 19, 2009), 237 medicallyattended ILI (MA-ILI)
ases arising from 12,581 patient visits were reported from
articipating Canadian sentinel sites. Children under 10
ears accounted for 33.8% of these cases. Pneumonia was
eported in 8.4% of the MA-ILI cases, increasing from none
n early October to 22.2% in the second week of Novem-
er. Comparing ILI cases with pneumonia to those without,
he median age was 30 years vs 21 years (p = 0.5); 50.0% vs
4.5% were females (p = 0.2); 0% vs 0.9% were health care
orkers (p = 1.0); median time from symptom onset to pri-
ary care visit was 5 days vs 2 days (p = 0.02); 0% vs 2.3%
eceived the current season’s inﬂuenza vaccine (p = 1.0),
.0% vs 0.5% received the pH1N1 inﬂuenza vaccine (p = 0.2),
5.0% vs 39.4% received a pneumococcal vaccine (p = 0.2);
% vs 3.3% had diabetes (p = 1.0) and 20.0% vs 23.4% had
sthma (p = 1.0).
Conclusion: Children under 10 years were disproportion-
tely affected but most cases were not life threatening. EMR
as able to rapidly detect the shifts in the pandemic severity
n real time. The proportion of ILI cases with pneumonia was
scalating during the initial phase of this study. Pneumonia
as associated with a longer time from symptom onset to
rimary care visit. With increasing sample size in this ongo-
ng study, statistical power to assess vaccine effectiveness
nd severity risk factors is anticipated to increase greatly.
oi:10.1016/j.ijid.2010.02.2209
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ystemic MRSA infections
. Rubinstein
Faculty of Medicine, Winnipeg, Canada
Systemic Staphylococcal infections were always a
readed complication of various injuries and for many
enturies meant amputation or death for the unfortunate
atient. MRSA has become since the 60’s a major cause for
ystemic infections and in various settings are responsible to
80% of all nosocomial bacteremias. In other settings, MRSA
s responsible ∼50% and in a recent survey of ICU infections
mong ∼14.000 patients the infection rate had decreased to
7% (Vincent et al JAMA 302;2323:2009). MRSA infections are
haracterized by various clinical presentations from mild-
o rapidly progressing and frequently with involvement of
ultiple organs includ. heart valvaes, bones, joints and
mplanted foreign bodies. Those locations, with the partic-
lar resistance pattern of MRSA, and only a few effective
ntibiotics to choose from, make MRSA infections partic-
larly difﬁcult to treat with a frequent need for surgery.
he frequent use of foreign bodies in therapy (IV catheters,
mplants,dialysis catheters, CNS shunts etc’) and the bio-
ogical avidity of this organism to these foreign materials
dd to the complexity of the infection. Quorum sensing and
he ability of the organism to create a bioﬁlm and to detach
rom the adherent colony add also to the complexity of these
nfections. Understanding of these biological mechanisms
nd being able to interfere should allow for some future
herapeutic measures. Evidently, meanwhile, hospital infec-
ion control and a possible future staphylococcal vaccine are
olutions to peruse. CA MRSA can be controlled by hyginic
easures as well as vaccine as this organism despite its low
otential to cause systemic infections is likely to stay for
any years.
oi:10.1016/j.ijid.2010.02.2210
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reatment of severe MRSA infections: Beyond Vancomycin
. Karchmer
Beth Israel Hospital, Boston, MA, USA
Vancomycin, as the gold standard for therapy of severe
RSA infections, particularly pneumonia, bacteremia, and
ndocarditis, has been questioned. In recent years reduced
ancomycin susceptibility of MRSA has been noted: minimum
nhibitory concentrations (MIC) have increased, isolates with
ntermediate susceptibility (MIC 4 to 16 $g/ml) [VISA] and
vertly resistant (MIC ‘‘32 $g/ml) [VRSA] have been noted,
nd importantly isolates of apparently vancomycin sus-
eptible MRSA with subpopulations exhibiting intermediate
usceptibility to vancomycin (survival at vancomycin con-
entrations’’ 4 $g/ml) so called heteroVISA [hVISA] have
een encountered. VISA and hVISA isolates may emerge
hen vancomycin therapy is suboptimal. Severe MRSA infec-
ions caused by isolates with vancomycin MIC’’ 1.5-2.0 $g/ml
nd hVISA have been associated with poor clinical outcome
